SCHEMBL5136646

SCHEMBL5136646

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(Cl)c(Cl)c1)CC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
TSHR P16473 2/20 0.35
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HDAC1 Q13547 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
SIGMAR1 Q99720 4/20 0.34
NR1I3 Q14994 1/20 0.34
CRHR1 P34998 4/20 0.34
BCHE P06276 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650928 0.93 C5AR1 (0.43) C5AR1TSHRUBE2MDCUN1D1KDM4E
SCHEMBL649094 0.93 C5AR1 (0.43) C5AR1TSHRUBE2MDCUN1D1KDM4E
SCHEMBL647602 0.91 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135678 0.91 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135713 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137864 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134910 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5134999 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135166 0.88 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135945 0.88 C5AR1 (0.57) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed